Analyst Price Targets — KOD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 11, 2026 12:00 pm | — | Chardan Capital | $61.00 | $41.38 | TheFly | Kodiak Sciences upgraded to Buy from Neutral at Chardan |
| March 27, 2026 1:15 pm | — | UBS | $80.00 | $37.00 | TheFly | Kodiak Sciences price target raised to $80 from $50 at UBS |
| March 27, 2026 10:04 am | Matthew Caufield | H.C. Wainwright | $58.00 | $37.00 | TheFly | Kodiak Sciences price target raised to $58 from $38 at H.C. Wainwright |
| March 26, 2026 6:08 pm | — | Jefferies | $56.00 | $39.76 | TheFly | Kodiak Sciences price target raised to $56 from $39 at Jefferies |
| January 22, 2026 11:07 am | Matthew Caufield | H.C. Wainwright | $38.00 | $26.71 | TheFly | Kodiak Sciences price target raised to $38 from $26 at H.C. Wainwright |
| January 7, 2026 5:44 am | Michael Yee | UBS | $50.00 | $25.05 | StreetInsider | UBS Starts Kodiak Sciences Inc. (KOD) at Buy |
| September 25, 2025 8:34 am | Gena Wang | Barclays | $17.00 | $15.49 | TheFly | Kodiak Sciences upgraded to Equal Weight from Underweight at Barclays |
| December 9, 2024 11:09 am | Michael Yee | Jefferies | $20.00 | $11.48 | StreetInsider | Jefferies Upgrades Kodiak Sciences Inc. (KOD) to Buy |
| September 24, 2024 10:04 am | Andrea Tan | Goldman Sachs | $2.00 | $2.43 | StreetInsider | Goldman Sachs Reiterates Sell Rating on Kodiak Sciences Inc. (KOD) |
| November 14, 2022 8:46 am | — | Morgan Stanley | $9.00 | $7.59 | Benzinga | Morgan Stanley Maintains Equal-Weight on Kodiak Sciences, Lowers Price Target to $9 |
Latest News for KOD
Algert Global LLC increased its stake in shares of Kodiak Sciences Inc. (NASDAQ: KOD) by 26.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 186,476 shares of the company's stock after purchasing an additional 38,546 shares during the quarter.
KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.
PALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026.
Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the first patients have been enrolled in the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KOD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.